3 substantial treatment failure, it is therefore recommended to monitor treatment efficacy every 2-3 48 years. Therapeutic efficacy studies, however, can present insurmountable logistical and financial 49 challenges in some settings in sub-Saharan Africa. Molecular surveillance of antimalarial resistance 50 is therefore an important proxy for treatment efficacy. However, the scale by which such studies 51 can be performed depends on the development of high-throughput protocols and the accessibility of 52
Background (word count (incl. conclusion): 3577) 64
In anticipation of novel emergence or geographic spread of especially artemisinin-resistant Plasmodium falciparum parasites (1-3), countries with malaria transmission are recommended to 66 test the efficacy of their recommended artemisinin-based combination therapies (ACTs) every 2-3 67 years (4). Therapeutic efficacy studies are often not feasible due to economic and practical 68 constraints in many settings in Sub-Saharan Africa (SSA). It has been suggested that molecular 69 surveillance of genetic polymorphisms associated with antimalarial resistance could complement 70 therapeutic efficacy studies (4-15) because these can provide early warning signs of decreasing 71 antimalarial efficacy (5). Molecular surveillance only requires sampling of P. falciparum infected 72 blood, which in turn can be acquired from finger prick samples, as used for malaria rapid diagnostic 73 tests (RDTs) (16, 17) . RDTs are now routinely used for malaria diagnostics in in SSA, and 74 molecular analysis on used RDTs may enable large-scale molecular surveillance of antimalarial 75 resistance (18) . Large-scale surveillance also requires highly efficient and cost-effective 76 methodologies for the genetic analysis of the parasite DNA. Novel, high-throughput protocols 77 based on next generation sequencing (NGS) technology have the potential to achieve this (19) (20) (21) . 78
79
The primary aim of this study was to evaluate collected RDTs as source of parasite DNA for NGS-80 based molecular surveillance of antimalarial resistance. A modified version of a recently published 81 NGS-based amplicon sequencing methodology was used (20) . The molecular approach investigated 82 SNPs and genes associated with tolerance/resistance towards the majority of currently available 83 antimalarial treatments in a high-throughput manner, applying massive parallel sequencing and a 84 custom-made sample-indexing approach. A secondary aim was to provide temporal molecular 85 marker data from the setting in Bissau, Guinea-Bissau from samples obtained from May 2014 until 86
April 2017, as well as a basic description of the demographic trends amongst malaria patients 87 versus non-malaria patients in the study area, by collecting minimal patient information together 88 with the RDTs. 89 90
Results

91
Evaluation of the applicability of RDTs as source of DNA for NGS-based molecular surveillance 92
PCR-corrected RDT positivity and negativity 93
In total, 14,933 RDTs were used to diagnose patients at the two health centres between May 2014 94 and April 2017, and collected. Out of these, 2,832 RDTs were positive. A flow chart depicting the 95 sample screening and selection process is shown in Figure 1 . All positive RDTs collected at the 96 Bandim health centre (and not at the Belem health centre) which were received in Denmark 97 (n=2,184, 77 % of the RDT positive samples) were subjected to DNA extraction. Samples that were 98 successfully found logged in the RDT database (n=1,879, 86 % of the DNA-extracted samples) 99 were then checked for PCR-positivity of the ribosomal 18S Plasmodium subunit. The overall PCR-100 corrected positivity amongst these samples was 74 % (n=1,390). Median age, sex-distribution and 101 season of collection indicated no trends in the occurrence of false positive RDTs (data not shown). 102 A total of 304 negative RDTs from the 2014 and 2015 transmission periods were also tested for 103
SNPs identified in pfk13 134
As PCR-positivity for PfK13 fragments was very low, only data from the latest of the transmission 135 periods is presented. A total of 311 samples collected during the 2016 transmission period were 136 partially or completely sequenced in pfK13, whereof 97 were successfully sequenced in the 137 propeller region. In total, 18 SNPs were identified in pfK13, only 3 of which were situated in the 138 propeller region, 2 of which are non-synonymous (R529K and T535M) ( Figure 4 ). In the N-139 terminal region, we identified 15 SNPs, 12 of which were non-synonymous ( Figure 4 ). None of the 140 identified SNPs occurred in more than two samples. 141
142
Demographic trends of RDT-positive versus RDT-negative patients 143
Sampling was carried out for 36 months, starting May 2014. Transmission periods were therefore 144 defined as periods of 12 months going from May one year up to and including April the following 145
year, which includes the high transmission period September to January. In order to compare years 146 and transmission periods, transmission periods have been named according to the year when 147 transmission started. The number of positive RDTs collected during the 2014, 2015 and 2016 148 transmission periods were 497, 1374 and 961, respectively ( Figure 5A ). The number of positive 149
RDTs collected during the 2014 transmission period was substantially lower than the numbers 150 collected in the two later transmission periods. Unexpected "dips" in the number of RDT positive 151 patients were seen during January and September 2016 ( Figure 5A ). 152
The median age of patients with a positive RDT was 19 years (interquartile range (IQR) 11-28) 153 ( Figure 5B ). When divided into age groups of <5 years, 5-9, 10-14 and 15, the number of patients 154 with positive RDTs were 190 (6 %), 327 (12 %), 428 (15 %) (children less than 15 years of age 155 combined = 945 (34 %)) and 1,847 (66 %) ( Figure 5C , 40 samples did not have age stated). The sex 156 distribution amongst RDT positive patients was 1,145 males (52 %) and 1,647 females (48 %) 157 ( Figure 5D , 40 samples did not have sex stated). 158
159
The total number of negative RDTs collected was 12,101. The number of negative RDTs collected 160 during the 2014, 2015 and 2016 transmission periods were 4,001, 4,362 and 3,738 (RDT negative 161 database only includes until February 19 th 2017), respectively. The median age of patients with a 162 negative RDT was 18 years (IQR = 4-30) ( Figure 5B ). When divided into age groups of <5 years, 163 5-9, 10-14 and 15, the number of patients with a negative RDT was 3,154 (26 %), 1,503 (13 %), 164 721 (6 %) and 6,638 (55 %) ( Figure 5C , 85 samples did not have age stated). The sex distribution 165 amongst RDT negative patients was 6,248 males (52 %) and 5,768 females (48 %) ( Figure 5D , 85 166 samples did not have sex stated). 167
168
In order to assess whether the proportion of adults was higher in the group of RDT positive patients 169 than in the general population, proportions were compared to that of the general population of the 170 country, estimated in 2015 as 41.7 % children below the age of 15 vs 58.3 % adults (32). The 171 proportion of adults within the group of RDT-positive patients was found to be significantly higher 172 than that within the general population (Pearsons chi-square, p = 0.05), while the proportion of 173 adults within the entire group of RDT-tested patients was not. samples, the NGS protocol tested in this study has therefore proven highly affordable and also 210 seems to remain efficient, compared to many other methods allowing trace-back to sample of 211 origin, despite a very varied PCR-success for resistance-conferring genes. If the actual sampling 212 costs are taken into consideration, the entire per sample cost still remains far cheaper than for dried 213 venous blood samples, due to such samples requiring further sampling materials, labour and 214 logistics. 215
216
Other noteworthy limitations of the current study, when considering the concept of large-scale 217 surveillance based on routine sampling of RDTs, include the fact that routine sampling of RDTs is 218 completely dependent on RDT availability. In our study, RDTs may have been out of stock during 219 January and September 2016, where unexplained "dips" in malaria frequency are seen for periods 220 of time, in which case inclusion numbers for these months would be biased. Such bias can only be 221 assessed if logs are kept by the clinics regarding their RDT availability, along with potential use of 222 expired batches of RDTs (which was not the case in our setting). Furthermore, the nested PCR 223 protocol which is required for the DNA extracted from RDTs, poses a much larger contamination 224 risk during PCR procedures, than a simplex PCR protocol (35, 36) . Finally, there are no sample 225 backups when sampling RDTs, which may become a logistical and ethical concern. 226 227
Molecular markers of antimalarial resistance 228
The high prevalence of pfmdr1 86N in the current study, resembles previously published data for 229 the same study area in 2010-2012 (approximately 80 %) (37), indicating a relatively stable 230 prevalence. The data corresponds well with the use of AL and the AL-derived selection of the 231 pfmdr1 c. 86 N (10, 38, 39) . Importantly however, a recently performed efficacy study indicates 232 that the efficacy of AL is still 94-95 % (25), indicating that the prevalence of the pfmdr1 c. 86 N at 233 levels between 88-97 % is not affecting AL treatment efficacy in this setting. AL (lumefantrine 234 specifically) has also been shown to select for the pfcrt 76K wildtype (40). However, our study 235 found a significant increase of the mutant pfcrt CVIET haplotype over the study period. A similar 236 trend has previously been observed in the same study area and QN usage was speculated to be the 237 cause (37, 41). However, it may also be that the two observed events (2010-2012 and 2014-2016) of 238 increasing levels of the CVIET haplotype represent "highs" in a more long-term fluctuation of this 239 haplotype. 240
241
The levels of the pfdhfr IRN triple mutant found in this study (fluctuating between 73-92 %) 242 indicate selection of this haplotype since earlier studies were conducted (in 2004; prevalence of 41 243 %) (42). Likewise, the current levels of the pfdhfr/pfdhps quadruple mutant (33-51 %) indicate 244 selection since previous studies were conducted (15 % quadruple mutant in 2004) (42). Large scale 245 use of IPTp may have contributed to this selection, since IPTp is the only SP-based treatment that is 246 still recommended and implemented in Guinea-Bissau (24), apart from a very recent deployment of 247 seasonal malaria chemoprevention (SMC by use of SP+amodiaquine) in a northern region of the 248 country (43). SP was never first-line treatment in Guinea-Bissau, but was recommended as second-249 line treatment from 1996-2007. Selection may also be caused by use of SP for self-treatment of 250 malaria, the use of sulfamethoxazole-trimethoprim for bacterial infections, and finally it is also 251 possible that quadruple mutants are imported from neighbouring countries where SP has been used 252 as first-line treatment and where mutant haplotypes have historically been more prevalent than in 253 . 254
255 Importantly, the current study revealed no SNPs of concern in pfK13 (47). Combined with the 256 previously published data regarding pfK13 polymorphisms from the area (20) Bissau has changed during the past decades and is now highly seasonal with epidemics occurring 288 from September, peaking in November and lasting through January (22, 23). Children aged <5 289 years no longer account for the majority of malaria cases as the median age is gradually increasing 290 (23). The 1 st -line treatment for malaria is artemether-lumefantrine (AL) (24), which was recently 291
shown to be effective in the Bissau area (25). Quinine (QN) is the 2 nd -and 3 rd -line treatment for 292 malaria (24) and intermittent preventive treatment in pregnancy (IPTp) is implemented (24). 293
294
RDT sampling 295
Positive and negative RDTs were collected from patients of all ages whom health workers 296 suspected might be infected with P. falciparum (typically associated with presence of a fever within 297 the last 24 hours), presenting at the Bandim or Belem health centres from May 2014 until April 298 2017. Patient age, sex and date of collection were written on the RDT and on a clinical records 299 form. All information was put into a folder on a daily basis, and subsequently entered into an 300 electronic database. RDTs were collected in a storage box containing silica gel, which was kept 301 dark at room temperature, and stored between 3 and 9 months before shipment to Denmark, where 302 they were stored between 0 and 9 months at room temperature before DNA extraction was 303 performed. 304 305 DNA extraction 306 DNA was extracted by the chelex method, as described previously (26) (29)). All amplicons pertaining to the same infection were barcoded with 321 the same unique set of custom-made indices in the 5' and 3' ends. All barcoded amplicons were 322 pooled prior to sequencing and sequenced in parallel. De-multiplexing of sequence data was 323 performed based on all of the unique index-combinations given to the samples during library 324 preparation. The original multiplex, non-nested amplification of gene-fragments were modified to 325 simplex, nested amplification of the same or slightly modified gene-fragments ( Figure 2 ) due to the 326 minute amount of DNA contained in RDT extracts (20) . As all PCRs were performed in simplex, 327 certain fragments were redesigned to accommodate all of the genetic positions of interest within a 328 single fragment (to reduce the number of PCRs), instead of two fragments (regarding pfdhps and 3'-329 pfmdr1). In these cases, certain areas of the fragments are not sequenced, as the paired-end 300 bp 330 sequencing is not long enough to sequence the entire fragment. All primers are listed in 331
supplementary Table 1 . 332 333
Controls and duplicates 334
The majority of samples were run once, with 10 % of samples run as duplicates. Control samples 335 used in the study consisted of DNA from well characterised parasites, namely 3D7, FCR3, DD2, 336 K1, 7G8, MRA-1238 and MRA-1239 (12) , the latter two of which are pfK13 controls. Other 337 controls consisted of patient samples from earlier studies, where the haplotypes within specific 338 genes are known, namely AA (pfdhps 436A+437A), AG (pfdhps 436A+437G), 540E (pfdhps 540E) 339 and 164L (pfdhfr 164L). An entire overview of control sample haplotypes is listed in supplementary 340 Table 2 . 341 342
Library preparation 343
PCRs were performed as described previously (20), with the following alterations: all fragments 344 were amplified individually, and as nested PCRs. The outer and the nested PCR programs were 345 identical to the previously published "gene-specific PCR", except that they consisted of 40 cycles 346 each. The nested PCR was performed with primers containing the overhangs, as was previously the 347 case for the "gene-specific PCR". The nested PCR products were pooled according to sample of 348 origin, prior to index PCR, as described previously. The index PCR was run according to the 349 original protocol (20) . All primers and corresponding fragments are listed in supplementary Table  350 1, and depicted in Figure 2 Table 1 Frequencies of haplotypes found during the transmission periods -2016 (May 2014 April 2017 
